Ultragenyx Pharmaceutical Inc.
RARE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001515673
In the last 90 days, Ultragenyx Pharmaceutical Inc. insiders filed 0 open-market purchases and 3 sales; 311 institutions reported holding it in 13F filings for Q2 2026, worth $3.55B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $1.64B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $127.6K in total
- 3
- 13F holdersQ2 2026, +13 vs. previous quarter
- 311
- 13F valueReported value at the end of Q2 2026
- $3.55B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $673.0M
- +20.1% year over year
- Net income, FY2025
- -$575.0M
- No comparable prior period
- Free cash flow, FY2025
- -$472.0M
- No comparable prior period
- Revenue, Q3 FY2026
- $173.0M
- +8.2% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $575.0M (85.4% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 23.6M
- Shares sold short
- Change
- +3.48M
- +17.3% vs. previous
- Days to cover
- 8.27
- At average daily volume
Superinvestors holding RARE, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding RARE at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Ultragenyx Pharmaceutical Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 19, 2026 (view filing)1:48 PM ET | Oct 15 | 4 days | Horn HowardChief Financial Officer | SSale | −7.07K | $15.27 | −$107.9K | −7.3%89.2K after | |
| Sep 15, 2026 (view filing)6:57 PM ET | Sep 15 | Same day | Huizenga Theodore AlanSVP, Chief Accounting Officer | SSale | −1.28K | $13.57 | −$17.4K | −1.9%67.9K after | 10b5-1 |
| Sep 8, 2026 (view filing)12:29 PM ET | Sep 3 | 5 days | Huizenga Theodore AlanSVP, Chief Accounting Officer | SSale | −161 | $13.99 | −$2.25K | −0.2%69.1K after | |
| Aug 4, 2026 (view filing)3:15 PM ET | Aug 3 | 1 day | Parschauer Karah HerdmanEVP and Chief Legal Officer | SSale | −1.90K | $24.92 | −$47.3K | −2.0%92.6K after | 10b5-1 |
| Aug 4, 2026 (view filing)3:13 PM ET | Aug 3 | 1 day | Horn HowardChief Financial Officer | SSale | −4.70K | $24.92 | −$117.0K | −4.6%96.3K after | 10b5-1 |
| Jul 6, 2026 (view filing)3:37 PM ET | Jul 1 | 5 days | Horn HowardChief Financial Officer | SSale | −4.70K | $33.13 | −$155.6K | −4.4%101.0K after | 10b5-1 |
| Jun 15, 2026 (view filing) | Jun 15 | Same day | Sanders Corazon (Corsee) D.Director | SSale | −2.00K | $25.05 | −$50.1K | −8.7%21.1K after | |
| Jun 15, 2026 (view filing) | Jun 15 | Same day | Parschauer Karah HerdmanEVP and Chief Legal Officer | SSale | −1.90K | $24.62 | −$46.8K | −2.0%94.5K after | 10b5-1 |
| Jun 1, 2026 (view filing) | Jun 1 | Same day | Horn HowardChief Financial Officer | SSale | −4.65K | $23.77 | −$110.6K | −4.2%105.7K after | 10b5-1 |
| May 18, 2026 (view filing) | May 18 | Same day | Suliman ShehnaazDirector | SSale | −5.74K | $25.12 | −$144.2K | −17.0%28.0K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 311 holdersThe largest institutional positions in Ultragenyx Pharmaceutical Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 10,654,276 | $355.7M | 0.01% | +3,354,678+46.0% | Added |
| RTW Investments, LP | 7,796,895 | $260.3M | 2.22% | +4,148,100+113.7% | Added |
| Vanguard Portfolio Management LLC | 6,790,135 | $226.7M | 0.01% | +1,404,143+26.1% | Added |
| AQR Capital Management LLC | 6,560,809 | $214.1M | 0.07% | +1,982,785+43.3% | Added |
| State Street Corp | 6,158,766 | $205.6M | 0.01% | +1,137,325+22.6% | Added |
| Vanguard Capital Management LLC | 4,296,491 | $143.5M | 0.00% | +106,660+2.5% | Added |
| Two Sigma Investments, LP | 3,621,200 | $120.9M | 0.09% | +1,415,380+64.2% | Added |
| Sands Capital Management, LLC | 3,158,368 | $105.5M | 0.39% | −56,165−1.7% | Reduced |
| Jacobs Levy Equity Management, Inc | 2,939,719 | $98.2M | 0.35% | +1,508,648+105.4% | Added |
| Frontier Capital Management Co LLC | 2,847,936 | $95.1M | 0.89% | +656,754+30.0% | Added |
Holders of 5% or more of RARE
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Ultragenyx Pharmaceutical Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Vanguard Portfolio Management LLC | 13G/A | 8.60%8.48M shares | +1.65 ppfrom 6.95% | Apr 29, 20263 filings | Oct 30, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 8.30%8.14M shares | +3.20 ppfrom 5.10% | Apr 24, 20252 filings | Jul 30, 2026 | SEC |
| RTW Investments, LP | 13G | 7.90%7.80M shares | – | Feb 14, 20234 filings | Aug 14, 2026 | SEC |
| State Street Corp | 13G | 7.60%7.54M shares | +1.30 ppfrom 6.30% | May 12, 20263 filings | Nov 10, 2026 | SEC |
| Madison Avenue Partners, LP | 13G | 6.40%6.31M shares | New | Oct 20, 20261 filing | Oct 20, 2026 | SEC |
Politician trades
All politician trades in RARE1 member of Congress reported 5 trades in Ultragenyx Pharmaceutical Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Oct 12, 2026 |  Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| Apr 7, 2026 | Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| Mar 9, 2026 | Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| Sep 12, 2025 | Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| Aug 14, 2025 | Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
House · CA · Oct 12, 2026
Buy$1K-$15K
House · CA · Apr 7, 2026
Buy$1K-$15K
House · CA · Mar 9, 2026
Buy$1K-$15K
House · CA · Sep 12, 2025
Buy$1K-$15K
House · CA · Aug 14, 2025
Buy$1K-$15K